Susanne Wiegand, Gunnar Wichmann, Jeannette Vogt, Kathrin Vogel, Annegret Franke, Thomas Kuhnt, Florian Lordick, Anne-Marie Scheuble, Peter Hambsch, Peter Brossart, Franz Georg Bauernfeind, Holger Kaftan, Georg Maschmeyer, Matthias Paland, Marc Münter, Victor Lewitzki, Nicole Rotter, Carmen Stromberger, Marcus Beck, Steffen Dommerich, Thomas Christoph Gauler, Gunnar Hapke, Orlando Guntinas-Lichius, Ursula Schröder, Martin Görner, Matthias G Hautmann, Felix Steger, Bálint Tamaskovics, Anett Schmiedeknecht, Andreas Dietz
Most of the patients with head and neck squamous cell carcinoma (HNSCC) are diagnosed with locally advanced disease. Standards of care for curative-intent treatment of this patient group are either surgery and adjuvant radio(chemo)therapy (aRCT) or definitive chemoradiation. Despite these treatments, especially pathologically intermediate and high-risk HNSCC often recur. The ADRISK trial investigates in locally advanced HNSCC and intermediate and high risk after up-front surgery if the addition of pembrolizumab to aRCT with cisplatin improves event-free sur-vival compared to aRCT alone...
2023: Frontiers in Oncology